Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (6): 625-634.doi: 10.19982/j.issn.1000-6621.20210737
• Original Articles • Previous Articles Next Articles
WANG Ning1, ZHENG Lu-yao1, MENG Xiu-juan2, LIU Hai-ting1, DING Yang-ming1, YAO Rong1, GUO Shao-chen1, LU Yu1()
Received:
2022-01-12
Online:
2022-06-10
Published:
2022-06-01
Contact:
LU Yu
E-mail:luyu4876@hotmail.com
Supported by:
CLC Number:
WANG Ning, ZHENG Lu-yao, MENG Xiu-juan, LIU Hai-ting, DING Yang-ming, YAO Rong, GUO Shao-chen, LU Yu. Distribution characteristics of N-acetyltransferase-2 genotypes and comparison methods of different genotyping in Chinese population[J]. Chinese Journal of Antituberculosis, 2022, 44(6): 625-634. doi: 10.19982/j.issn.1000-6621.20210737
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20210737
发表时间 | 期刊 | 单位 | 研究对 象数量 | 民族 | 人群构成 | NAT2基因多 态性检测方法 | 研究编号 |
---|---|---|---|---|---|---|---|
2011年[ | 中国防痨杂志 | 广州市胸科医院 | 155 | 汉族 | 结核病患者 | PCR测序 | 广州-2011 |
2012年[ | Clinical and Experimental Pharmacology and Physiology | 解放军第309医院 | 208 | 不明确 | 结核病患者 | PCR测序 | 北京-2012 |
2006年[ | Disease Markers | 中南大学附属湘雅医院 | 294 | 汉族 | 肺癌患者及健康对照者 | PCR-RFLP | 长沙-2006 |
2012年[ | Frontiers in Bioscience (Elite edition) | 中国科学院上海分院及上海市疾病预防控制中心 | 336a | 汉族 | 膀胱癌患者及健康对照者 | PCR-RFLP | 上海-2012 |
2015年[ | 中华传染病杂志 | 复旦大学附属华山医院和上海交通大学医学院附属同仁医院 | 108 | 汉族 | 结核病患者 | PCR测序 | 上海-2015 |
2016年[ | Oncotarget | 华南理工大学等 | 951b | 不明确 | 膀胱癌患者及健康对照者 | iPLEX Gold Assay | 上海-2016 |
2016年[ | Journal of the Chinese Medical Association | 中国台湾台北荣民总医院 | 736 | 不明确 | 胃癌患者及健康对照者 | SNP特异 性PCR | 台北-2016 |
2009年[ | Cancer Detection and Prevention | 郑州大学第一附属医院 | 420 | 汉族 | 膀胱癌患者及健康对照者 | PCR-RFLP | 郑州-2009 |
2021年[ | Acta Medica Mediterranea | 广西医科大学第一附属医院等 | 2091 | 汉族 | 急性髓系白血病(非M3)患者及健康对照者 | SNaPshot | 南宁-2021 |
2004年[ | Acta Pharmacologica Sinica | 中国科学院上海分院等 | 163 | 汉族 | 老年性痴呆患者及健康对照者 | PCR-RFLP | 上海-2004 |
研究编号 | NAT2快代谢基因型 | NAT2中间代谢基因型 | NAT2慢代谢基因型 | 合计 |
---|---|---|---|---|
广州-2011 | 36(23.3) | 85(54.8) | 34(21.9) | 155 |
北京-2012 | 40(37.4) | 54(50.5) | 13(12.1) | 107 |
长沙-2006 | 47(23.9) | 112(56.9) | 38(19.2) | 197 |
上海-2012 | 102(33.4) | 148(48.5) | 55(18.1) | 305 |
上海-2015 | 36(40.9) | 46(52.3) | 6(6.8) | 88 |
上海-2016 | 137(29.0) | 258(54.5)a | 78(16.5) | 473 |
上海-2004 | 37(33.0) | 61(54.5) | 14(12.5) | 112 |
郑州-2009 | 72(34.0) | 112(52.8) | 28(13.2) | 212 |
台北-2016 | 108(29.3) | 199(54.1) | 61(16.6) | 368 |
南宁-2021 | 419(21.0) | 965(48.4) | 609(30.6) | 1993 |
合计 | 1034(25.8) | 2040(50.9) | 936(23.3) | 4010 |
等位基因 | 分类 | 单体型 | 广州-2011 | 北京-2012 | 上海-2015 | 长沙-2006 | 上海-2012 | 郑州-2009 | 上海-2016 | 台北-2016 | 南宁-2021 | 上海-2004 | 合计 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
*4 | R | CTCGAG | 157(50.65) | 128(59.81) | 115(65.34) | 178(45.18) | 339(55.57) | 251(59.20) | 521(56.14) | 412(55.98) | 1737(43.58) | 132(58.93) | 3970(49.61) |
*13 | R | TTCGAG | 0(0.00) | 2(0.93) | 3(1.70) | 22(5.58) | 9(1.48) | 2(0.47) | 2(0.22) | 0(0.00) | 66(1.66) | 3(1.34) | 109(1.36) |
*11A | R | CTTGAG | 0(0.00) | 0(0.00) | 0(0.00) | 3(0.76) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 3(0.04) |
*12A | R | CTCGGG | 0(0.00) | 4(1.87) | 0(0.00) | 0(0.00) | 0(0.00) | 3(0.71) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 7(0.09) |
*12B | R | TTCGGG | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 4(0.66) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 4(0.05) |
*12C | R | CTTGGG | 0(0.00) | 0(0.00) | 0(0.00) | 3(0.76) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 3(0.04) |
*6A | S | TTCAAG | 89(28.71) | 34(15.89) | 14(7.95) | 78(19.80) | 138(22.62) | 87(20.52) | 222(23.92) | 184(25.00) | 1264(31.71) | 46(20.54) | 2156(26.94) |
*7B | S | TTCGAA | 44(14.19) | 36(16.82) | 35(19.89) | 70(17.77) | 61(10.00) | 63(14.86) | 152(16.38) | 117(15.90) | 745(18.69) | 38(16.96) | 1361(17.01) |
*5B | S | CCTGGG | 15(4.84) | 0(0.00) | 2(1.14) | 11(2.79) | 21(3.44) | 10(2.36) | 30(3.23) | 20(2.72) | 174(4.37) | 4(1.79) | 287(3.59) |
*6B | S | CTCAAG | 0(0.00) | 0(0.00) | 1(0.57) | 14(3.55) | 32(5.25) | 1(0.24) | 0(0.00) | 3(0.41) | 0(0.00) | 0(0.00) | 51(0.64) |
*7A | S | CTCGAA | 0(0.00) | 5(2.34) | 0(0.00) | 9(2.28) | 6(0.98) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 20(0.25) |
*5A | S | CCTGAG | 2(0.65) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 7(1.65) | 1(0.11) | 0(0.00) | 0(0.00) | 0(0.00) | 10(0.12) |
*5C | S | CCCGGG | 3(0.97) | 0(0.00) | 0(0.00) | 2(0.51) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 5(0.06) |
*5D | S | CCCGAG | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 1(0.45) | 1(0.01) |
*6J | S | TTCAAA | 0(0.00) | 1(0.47) | 6(3.41) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 7(0.09) |
*6N | S | TTTAAG | 0(0.00) | 0(0.00) | 0(0.00) | 4(1.02) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 4(0.05) |
*10a | S | CTCGAG | 0(0.00) | 2(0.93) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 2(0.02) |
*19a | S | CTCGAG | 0(0.00) | 2(0.93) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 0(0.00) | 2(0.02) |
基因型 | 频数 | NAT2实际基因型 | 6SNP位点多态性 | 3SNP法推断基因型 | 2SNP法推断基因型 |
---|---|---|---|---|---|
*4/*4 | 1366 | R | CC TT CC GG AA GG | R | R |
*4/*12A | 13 | R | CC TT CC GG AG GG | R | R |
*4/*12B | 3 | R | CT TT CC GG AG GG | R | I |
*4/*13A | 88 | R | CT TT CC GG AA GG | R | I |
*13A/*13A | 10 | R | TT TT CC GG AA GG | R | S |
*4/*11A | 4 | R | CC TT CT GG AA GG | R | R |
*4/*5A | 6 | I | CC CT CT GG AA GG | I | I |
*4/*5B | 178 | I | CC CT CT GG AG GG | I | I |
*4/*5C | 6 | I | CC CT CC GG AG GG | I | I |
*4/*5D | 1 | I | CC CT CC GG AA GG | I | I |
*4/*6A | 1452 | I | CT TT CC AG AA GG | I | I |
*4/*6B | 139 | I | CC TT CC AG AA GG | I | R |
*4/*6J | 8 | I | CT TT CC AG AA AG | S | I |
*4/*6N | 1 | I | CT TT CT AG AA GG | I | I |
*4/*7A | 7 | I | CC TT CC GG AA AG | I | R |
*4/*7B | 838 | I | CT TT CC GG AA AG | I | I |
基因型 | 频数 | NAT2实际基因型 | 6SNP位点多态性 | 3SNP法推断基因型 | 2SNP法推断基因型 |
*4/*10 | 2 | I | CC TT CC GG AA GG | R | R |
*4/*19 | 1 | I | CC TT CC GG AA GG | R | R |
*6A/*11 | 1 | I | CT TT CT AG AA GG | I | I |
*7A/*11A | 2 | I | CC TT CT GG AA AG | I | R |
*7A/*12B | 4 | I | CT TT CC GG AG AG | I | I |
*7A/*13A | 2 | I | CT TT CC GG AA AG | I | I |
*6A/*13 | 35 | I | TT TT CC AG AA GG | I | S |
*6A/*12A | 3 | I | CT TT CC AG AG GG | I | I |
*7B/*13 | 18 | I | TT TT CC GG AA AG | I | S |
*5B/*13 | 4 | I | CT CT CT GG AG GG | I | S |
*7B/*12C | 3 | I | CT TT CT GG AG AG | I | I |
*13/*6N | 2 | I | TT TT CT AG AA GG | I | S |
*11A/*6N | 1 | I | CT TT TT AG AA GG | I | I |
*5A/*5B | 9 | S | CC CC TT GG AG GG | S | S |
*5A/*6A | 6 | S | CT CT CT AG AA GG | S | S |
*5B/*5B | 9 | S | CC CC TT GG GG GG | S | S |
*5B/*6A | 93 | S | CT CT CT AG AG GG | S | S |
*5B/*7B | 70 | S | CT CT CT GG AG AG | S | S |
*5C/*6A | 1 | S | CT CT CC AG AG GG | S | S |
*6A/*6A | 374 | S | TT TT CC AA AA GG | S | S |
*6A/*6B | 38 | S | CT TT CC AA AA GG | S | I |
*6A/*7B | 482 | S | TT TT CC AG AA AG | S | S |
*6A/*19 | 1 | S | CT TT CC AG AA GG | I | I |
*6B/*6B | 2 | S | CC TT CC AA AA GG | S | R |
*6B/*7A | 4 | S | CC TT CC AG AA AG | S | R |
*6B/*7B | 4 | S | CT TT CC AG AA AG | S | I |
*6J/*7B | 1 | S | TT TT CC AG AA AA | S | S |
*7A/*7A | 1 | S | CC TT CC GG AA AA | S | R |
*7A/*7B | 6 | S | CT TT CC GG AA AA | S | I |
*7B/*7B | 149 | S | TT TT CC GG AA AA | S | S |
[1] |
欧阳晓春, 刘振华. NAT2基因多态性与疾病遗传易感性的关系. 医学综述, 2006, 12(1): 20-21. doi: 10.3969/j.issn.1006-2084.2006.01.009.
doi: 10.3969/j.issn.1006-2084.2006.01.009 |
[2] |
Hein DW, Millner LM. Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy-a focused review. Expert Opin Drug Metab Toxicol, 2021, 17(1): 9-21. doi: 10.1080/17425255.2021.1840551.
doi: 10.1080/17425255.2021.1840551 URL |
[3] |
陈亮亮, 胡文豪, 刘魁, 等. N-乙酰基转移酶2基因多态性与膀胱癌的易感性在亚洲人群中的Meta分析. 临床泌尿外科杂志, 2014, 29(2): 118-124. doi: 10.13201/j.issn.1001-1420.2014.02.009.
doi: 10.13201/j.issn.1001-1420.2014.02.009 |
[4] |
Chen HC, Cao YF, Hu WX, et al. Genetic polymorphisms of phase Ⅱ metabolic enzymes and lung cancer susceptibility in a population of Central South China. Dis Markers, 2006, 22(3): 141-152. doi: 10.1155/2006/436497.
doi: 10.1155/2006/436497 URL |
[5] |
Quan L, Chattopadhyay K, Nelson HH, et al. Differential association for N-acetyltransferase 2 genotype and phenotype with bladder cancer risk in Chinese population. Oncotarget, 2016, 7(26): 40012-40024. doi: 10.18632/oncotarget.9475.
doi: 10.18632/oncotarget.9475 pmid: 27223070 |
[6] |
Bandmann O, Vaughan J, Holmans P, et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet, 1997, 350(9085): 1136-1139. doi: 10.1016/s0140-6736(97)03495-8.
doi: 10.1016/s0140-6736(97)03495-8 pmid: 9343502 |
[7] |
Zhang M, Wang S, Wilffert B, et al. The association between the NAT 2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol, 2018, 84(12): 2747-2760. doi: 10.1111/bcp.13722.
doi: 10.1111/bcp.13722 pmid: 30047605 |
[8] |
首都医科大学附属北京胸科医院, 《中国防痨杂志》编辑委员会. 结核病患者N-乙酰基转移酶2编码基因多态性检测与异烟肼合理用药专家共识. 中国防痨杂志, 2021, 43(11): 1107-1112. doi: 10.3969/j.issn.1000-6621.2021.11.001.
doi: 10.3969/j.issn.1000-6621.2021.11.001 |
[9] |
Walker K, Ginsberg G, Hattis D, et al. Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT 2 activity. J Toxicol Environ Health B Crit Rev, 2009, 12(5/6): 440-472. doi: 10.1080/10937400903158383.
doi: 10.1080/10937400903158383 URL |
[10] |
Lu JF, Cao XM, Liu ZH, et al. Genetic analysis of N-acetyltransferase polymorphism in a Chinese population. Acta Pharmacologica Sinica, 1998, 19(4): 347-351. doi: 10.1016/S0300-483X(98)00043-2.
doi: 10.1016/S0300-483X(98)00043-2 pmid: 10375782 |
[11] |
Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics, 2012, 13(1): 31-41. doi: 10.2217/pgs.11.122.
doi: 10.2217/pgs.11.122 URL |
[12] |
Selinski S, Blaszkewicz M, Lehmann ML, et al. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics, 2011, 21(10): 673-678. doi: 10.1097/FPC.0b013e3283493a23.
doi: 10.1097/FPC.0b013e3283493a23 URL |
[13] |
Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet, 2001, 68(4): 978-989. doi: 10.1086/319501.
doi: 10.1086/319501 pmid: 11254454 |
[14] |
Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet, 2005, 76(3): 449-462. doi: 10.1086/428594.
doi: 10.1086/428594 pmid: 15700229 |
[15] |
Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet, 2003, 73(5): 1162-1169. doi: 10.1086/379378.
doi: 10.1086/379378 pmid: 14574645 |
[16] |
An H, Wu XQ, Wang ZY, et al. NAT2 and CYP2E 1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol, 2012, 39(6): 535-543. doi: 10.1111/j.1440-1681.2012.05713.x.
doi: 10.1111/j.1440-1681.2012.05713.x. URL |
[17] |
沈婷婷, 张琴, 张文宏, 等. 中国汉族结核病患者 N-乙酰基转移酶2基因型与药物性肝损伤以及抗结核疗效的关系. 中华传染病杂志, 2015, 33(6): 327-330. doi: 10.3760/cma.j.issn.1000-6680.2015.06.003.
doi: 10.3760/cma.j.issn.1000-6680.2015.06.003 |
[18] | 李昕洁, 王云南, 邹永红, 等. 155例汉族结核病患者N-乙酰基转移酶2(NAT2)基因多态性分析. 中国防痨杂志, 2011, 33(6): 357-360. |
[19] |
Song DK, Xing DL, Zhang LR, et al. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev, 2009, 32(5/6): 416-423. doi: 10.1016/j.cdp.2009.02.003.
doi: 10.1016/j.cdp.2009.02.003 URL |
[20] |
Ma QW, Lin GF, Chen JG, et al. N-Acetyltransferase 2 genotype, exfoliated urothelial cells and benzidine exposure. Front Biosci (Elite Ed), 2012, 4(5): 1966-1974. doi: 10.2741/517.
doi: 10.2741/517 |
[21] |
Xie Q, Li H, Huang L, et al. N-Acetyltransferase 2 (NAT2) single nucleotide polymorphisms in patients with adult acute myeloid leukemia (NON-M3): A case-control study. Acta Medica Mediterranea, 2021, 37(4): 2449-2456. doi: 10.19193/0393-6384_2021_4_382.
doi: 10.19193/0393-6384_2021_4_382 |
[22] | Guo WC, Lin GF, Zha YL, et al. N-Acetyltransferase 2 gene polymorphism in a group of senile dementia patients in Shanghai suburb. Acta Pharmacol Sin, 2004, 25(9): 1112-1117. |
[23] |
Chang CH, Huang YS, Perng CL, et al. N-Acetyltransferase 2 (NAT2) genetic variation and the susceptibility to noncardiac gastric adenocarcinoma in Taiwan. J Chin Med Assoc, 2016, 79(3): 105-110. doi: 10.1016/j.jcma.2015.08.011.
doi: 10.1016/j.jcma.2015.08.011 URL |
[24] |
Shishikura K, Hohjoh H, Tokunaga K. Novel allele containing a 190C>T nonsynonymous substitution in the N-acetyltransferase (NAT2) gene. Hum Mutat, 2000, 15(6):581. doi: 10.1002/1098-1004(200006)15:6<581::AID-HUMU17>3.0.CO;2-V.
doi: 10.1002/1098-1004(200006)15:6<581::AID-HUMU17>3.0.CO;2-V |
[1] | TIAN Li, ZHOU Wei, HUANG Xing, WU Xian-wei, ZHANG Hui-yong, LU Zhen-hui, ZHANG Shao-yan. Analysis of gene mutation characteristics of isoniazid-resistant Mycobacterium tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 354-361. |
[2] | YANG Ting-ting, GAO Qian. The tuberculosis drug-resistance and transmission surveillance network based on whole genome sequencing data [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 645-648. |
[3] | LUO Dan, QIN Hui-fang, YE Jing, ZHAO Jin-ming, QIN Yi-xiang, LAN Ru-shu. Analysis on gene mutation characteristics of drug resistant Mycobacterium tuberculosis and its correlation with genotypes in Guangxi [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 596-601. |
[4] | BAI Hua, GUO Jing-wei, HU Pei-lei, YI Song-lin, WEN Jia, LIU Feng-ping, TAN Yun-hong, BAI Li-qiong. Analysis of drug resistance surveillance results of Mycobacterium tuberculosis in Hu’nan Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 364-369. |
[5] | CHENG Jun, ZHANG Can-you, CHEN Hui, ZHANG Hui, ZHAO Yan-lin. Strengthen tuberculosis control strategy in key populations according to local conditions [J]. Chinese Journal of Antituberculosis, 2021, 43(3): 217-221. |
[6] | ZHANG Hui, CHENG Jun, YU Yan-ling, SHEN Xin, LU Wei, WANG Xiao-meng, YAO Yu-xia, HOU Shuang-yi, LI Jian-wei, ZHAO Jin-ming, XIA Lan, XU Lin, ZHANG Can-you, ZHAO Fei, XIA Yin-yin, CHEN Hui, WANG Li-xia. Evaluation of the effectiveness of community-based pulmonary tuberculosis active case-finding among key populations: a multicenter prospective cohort study [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1248-1259. |
[7] | XIA Jing, CHEN Lei, QIN Jia, ZHU Xi, LI Jun. Analysis of pulmonary tuberculosis surveillance results of entry-exit population at Shanghai port from 2014 to 2020 [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1297-1301. |
[8] | Beijing Chest Hospital,Capital Medical University,Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on polymorphism detection of N-acetyltransferase-2 encoding gene and appropriate isoniazid dosing for tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(11): 1107-1112. |
[9] | WU Hui-zhong, ZHOU Fang-jing, LIAO Qing-hua, CHEN Liang, LAI Xiao-yu, YU Mei-ling, WEN Wen-pei, ZHOU Lin. Analysis of the implementation effect of active tuberculosis screening strategy in permanent residents aged 5 and older in Lianjiangkou Town, Guangdong in 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1032-1038. |
[10] | ZHU Li-mei, CHEN Can-can, CHEN Wei, HU Xiao-guang, ZHANG Ya-nan, MA Jun-yang. To formulate prevention and control strategy for latent tuberculosis infection population in China [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 794-798. |
[11] | LI Tao, DU Xin, CHEN Wei, HUANG Fei, ZHAO Yan-lin, ZHANG Hui. Review and prospect of tuberculosis management information surveillance and monitoring in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 657-661. |
[12] | DU Xin, LI Tao, LI You, SUN Miao-miao, WANG Ni, ZHANG Hui, ZHAO Yan-lin, HUANG Fei. Pilot exploration of a New TB Surveillance System based on the National Health Security Project Construction Plan [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 662-666. |
[13] | WANG Ni, HUANG Fei, LI Tao, LI You, SUN Miao-miao, ZHANG Hui, ZHAO Yan-lin, DU Xin. Establishment and validation of the standard basic dataset for tuberculosis surveillance [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 667-670. |
[14] | HONG Chuang-yue, YANG Ting-ting, LI Jin-li, LI Shuang-jun, WU Li-kai, YANG Zheng, TAN Wei-guo. Analysis of characteristic of resistant gene mutations among multidrug-resistant Mycobacterium tuberculosis in Shenzhen [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 583-589. |
[15] | CHENG Jun, LIU Jian-jun. Current status and progress of surveillance and automated-alert for tuberculosis in school [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 436-441. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||